Exchange of the VP5 of infectious bursal disease virus in a serotype I strain with that of a serotype II strain reduced the viral replication and cytotoxicity

A reassortment vaccine candidate of the novel variant infectious bursal disease virus

Infectious bursal disease (IBD), caused by infectious bursal disease virus (IBDV), is the most important immunosuppressive disease threatening the poultry industry worldwide. Recently, the novel variant IBDV has been emerging in large-scale in Asia including China and is becoming a new threat to the healthy development of the poultry industry, but no ideal vaccine is available. Therefore, it is necessary and urgent to develop a new vaccine against the novel variant IBDV. In this study, based on the skeleton of an attenuated vaccine strain Gt, a reassortment virus strain rGtVarVP2 was constructed for the first time, which could express the main protective antigen VP2 of the novel variant IBDV and replicate well in cell culture. Subsequently, the safety and effectiveness of rGtVarVP2 were further evaluated using animal experiments. The rGtVarVP2 is nonpathogenic to specific-pathogen-free (SPF) chicken. The immunization of rGtVarVP2 could induce the specific neutralizing antibodies against the novel variant IBDV. The challenge protection tests further confirmed the effectiveness of the IBDV reassortment virus rGtVarVP2. No atrophy and obvious lesions were observed in the immunization group while the bursae of non-immunization control group were severely destroyed after challenge, which showed that rGtVarVP2 could provide complete protection against the novel variant IBDV. These data indicate that the vaccine candidate (rGtVarVP2 strain) is safe and effective, which is of great significance for comprehensive control of IBD and healthy breeding.

Reverse genetics approaches for live-attenuated vaccine development of infectious bursal disease virus

Infectious bursal disease (IBD), which is caused by infectious bursal disease virus (IBDV) infection, leads to severe immunosuppression in young chickens and results in significant economic losses in the poultry industry. To date, vaccination with live-attenuated vaccine (LAV) is a convenient method to provide effective protection against IBDV infection. Classical attenuated viruses are usually obtained by either passaging virus in cultured cells or natural isolation. However, these empiric attenuation methods, which are time-consuming and not guaranteed, are not reliable for emergent antigenic variant and very virulent IBDV strains. The reverse genetics (RG) system opens a new avenue for the development of IBDV LAV. In this review, we summarize the current knowledge on the biological characteristics of IBDV structure and genome organization, as well as the established RG systems. We also describe the details for the strategies used to develop IBDV LAV based on the RG systems.

VP5-deficient mutant virus induced protection against challenge with very virulent infectious bursal disease virus of chickens

A mutant infectious bursal disease virus (IBDV) deficient in expressing VP5, rGx-F9VP2DeltaVP5, was generated using reverse genetics technology. In comparison to the characteristics of rGx-F9VP2 virus in vitro, the mutant virus demonstrated lower viral titer and cytopathogenicity. To understand the role of VP5 in the pathogenicity of IBDV in vivo, animal experiments were conducted. rGx-F9VP2DeltaVP5 caused reduced bursal lesion of SPF chickens compared to rGx-F9VP2. Although rGx-F9VP2DeltaVP5 induced lower serum antibody than rGx-F9VP2 did, both inoculated groups were fully protected against vvIBDV challenge 4 weeks post-inoculation. In addition, immunosuppression induced by VP5-deficient virus was studied in 2-week-old SPF chickens immunized with AIV inactivated vaccine. And there was reduced immunosuppression as shown in our experimental results. The results showed that AIV hemagglutination inhibition (HI) antibodies of the rGx-F9VP2DeltaVP5 inoculated group were similar to those of the mock-inoculated group, however, they were higher than those of the rGx-F9VP2 inoculated group, indicating that deficiency of VP5 decreased the immunosuppression of rGx-F9VP2DeltaVP5 in chickens. All data indicated that VP5 played an important role in viral replication and pathogenesis both in vitro and in vivo. The VP5-deficient mutant virus could be a good candidate as a marked vaccine.